Patients received once-monthly doses of the @-month formulation of paliperidone palmitate ( @ , @ , @ , or @ mg eq ) during the transition phase , followed by a single dose of the @-month formulation ( @ times the stabilized dose of once-monthly paliperidone palmitate ) during the maintenance phase .